OBJECTIVE: To evaluate whether the efficacy of high-dose chemotherapy in the treatment of primary well-differentiated osteosarcoma is superior to moderate-dose chemotherapy. METHODS: Cochrane systematic review method was used to retrieve literatures from MEDLINE, Embase, OVID, Cochrane Library database of clinical trials, Chinese Biomedical Literature Database CD-ROM, as well as manual searching from "China Oncology", "Chinese Journal of Clinical Oncology", "Cancer" etc. Meta-analysis was performed using the RevMan 5.0 software. RESULTS: A total of four studies, 937 cases of primary, non-metastatic, well-differentiated limb osteosarcoma patients were enrolled in the study. Meta-analysis results suggested that compared with moderate-dose group, 5-year disease-free survival, 5-year overall survival rate, the local recurrence rate, proportion of histologic response in good status, limb salvage rate showed no significant difference in high-dose chemotherapy group (All P > 0.05); good and poor response of preoperative chemotherapy tumor histologic of 5-year disease-free survival showed statistical difference (RR = 1.55; 95% CI: 1.19-2.00; P = 0.0009). CONCLUSION: High-dose chemotherapy for the treatment of primary osteosarcoma is not better than moderate-dose chemotherapy. It is expected that high quality of randomized controlled trials were performed to provide more reliable evidence in the future.
OBJECTIVE: To evaluate whether the efficacy of high-dose chemotherapy in the treatment of primary well-differentiated osteosarcoma is superior to moderate-dose chemotherapy. METHODS: Cochrane systematic review method was used to retrieve literatures from MEDLINE, Embase, OVID, Cochrane Library database of clinical trials, Chinese Biomedical Literature Database CD-ROM, as well as manual searching from "China Oncology", "Chinese Journal of Clinical Oncology", "Cancer" etc. Meta-analysis was performed using the RevMan 5.0 software. RESULTS: A total of four studies, 937 cases of primary, non-metastatic, well-differentiated limb osteosarcomapatients were enrolled in the study. Meta-analysis results suggested that compared with moderate-dose group, 5-year disease-free survival, 5-year overall survival rate, the local recurrence rate, proportion of histologic response in good status, limb salvage rate showed no significant difference in high-dose chemotherapy group (All P > 0.05); good and poor response of preoperative chemotherapy tumor histologic of 5-year disease-free survival showed statistical difference (RR = 1.55; 95% CI: 1.19-2.00; P = 0.0009). CONCLUSION: High-dose chemotherapy for the treatment of primary osteosarcoma is not better than moderate-dose chemotherapy. It is expected that high quality of randomized controlled trials were performed to provide more reliable evidence in the future.
Authors: M Hudson; M R Jaffe; N Jaffe; A Ayala; A K Raymond; H Carrasco; S Wallace; J Murray; R Robertson Journal: J Clin Oncol Date: 1990-12 Impact factor: 44.544
Authors: R L Souhami; A W Craft; J W Van der Eijken; M Nooij; D Spooner; V H Bramwell; R Wierzbicki; A J Malcolm; A Kirkpatrick; B M Uscinska; M Van Glabbeke; D Machin Journal: Lancet Date: 1997-09-27 Impact factor: 79.321
Authors: J S Whelan; R C Jinks; A McTiernan; M R Sydes; J M Hook; L Trani; B Uscinska; V Bramwell; I J Lewis; M A Nooij; M van Glabbeke; R J Grimer; P C W Hogendoorn; A H M Taminiau; H Gelderblom Journal: Ann Oncol Date: 2011-10-19 Impact factor: 32.976
Authors: Siobhan Simpson; Mark David Dunning; Simone de Brot; Llorenç Grau-Roma; Nigel Patrick Mongan; Catrin Sian Rutland Journal: Acta Vet Scand Date: 2017-10-24 Impact factor: 1.695